Catalent Applied Drug Delivery Institute Appoints Jim Spavins To Advisory Board




SOMERSET, N.J. – July 26, 2017 — The Catalent Applied Drug Delivery Institute today announced that Mr. Jim Spavins, a veteran pharmaceutical industry executive, has joined the Institute’s Advisory Board. Mr. Spavins brings over 36 years of industry and academic experience to the Institute, having previously worked at all levels of research and development, reaching the position of Senior Vice President of Pfizer's Global Pharma Therapeutics Pharmaceutical Sciences group before starting his own consulting business, Spavins Consulting LLC.

“I look forward to working with the CADDI Board to help rapidly advance innovative drug delivery solutions to patients,” Mr. Spavins commented. “There has never been a more exciting time to leverage astonishing scientific advances in disease understanding with optimum delivery technology.”

“I’m very pleased to welcome Jim to the Institute,” added Dr. Cornell Stamoran, Founder of the Catalent Applied Drug Delivery Institute and Catalent’s VP Strategy. “He brings us a wealth of scientific and leadership experience, front line exposure to translational drug delivery, and a strong passion to enhance patient focus during drug development.”

Mr. Spavins has worked across large and small R&D groups within all the technical disciplines of chemistry, manufacturing and controls (CMC) development, as well as regulatory, quality, clinical supply, commercial manufacture, and economic analysis. His successful development projects have included in-house discovery programs, as well as working with small start-ups to bring licensed or acquired programs through development. In addition, Mr. Spavins has broad experience with of a wide network of contract development and manufacturing organizations (CDMOs) and other partners to advance programs.

Mr. Spavins holds a bachelor’s degree in chemistry from Queens College, New York, as well as a Master of Arts degree in analytical chemistry, and a Master of Science degree in chemical engineering, both from University of Buffalo, New York.[ends]

Media Contacts: 

Chris Halling
+44 (0)7580 041073
chris.halling@catalent.com

Richard Kerns
+44 (0) 161 728 5880
richard@nepr.eu

Notes for Editors

About Catalent Applied Drug Delivery Institute

Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.For more details on the Catalent Institute, visit www.drugdeliveryinstitute.com and follow the Catalent Institute on Twitter: @DrugDeliveryIns

About Catalent 

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

More products. Better treatments. Reliably supplied.™